immunomodulator

出典: meddic

biological response modifierimmunologic factorimmunological factorimmunomodulatory agent


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/10/28 23:44:50」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Structure elucidation and immunomodulatory activity in vitro of a xylan from roots of Cudrania tricuspidata.
  • Shi L1, Dong Q2, Ding K3.Author information 1College of Life Science, Qufu Normal University, Qufu 273165, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China; Temasek Applied Science School, Temasek Polytechnic, 21 Tampines Avenue 1, 529757 Singapore, Singapore. Electronic address: slsql2006@aliyun.com.2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China.3Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China. Electronic address: kding@mail.shcnc.ac.cn.AbstractTo discover new immunomodulator in the food industry, a water-soluble polysaccharide, CTPB1 was obtained from roots of Cudrania tricuspidata (Carr.) Bur. The average molecular weight of this polysaccharide was estimated to be 4.0×10(4)Da. Monosaccharide composition analysis indicated that the only neutral sugar present in this polysaccharide was xylose. From methylation analysis and (1)H and (13)C NMR spectroscopy, the structure of CTPB1 was deduced to be (4-O-methyl-d-glucurono)-d-xylan, with the 4-O-methyl-d-glucopyranosyluronic acid group linked to O-2 of a (1→4)-β-d-xylan. The repeating unit of CTPB1 is composed of one non-reducing terminal residue of 4-O-methyl-d-glucuronic acid on every four xylose residues. Immunomodulatory activity assays in vitro showed that CTPB1 may induce the proliferation of mouse splenocytes. It was suggested that CTPB1 could be a potential immunostimulant used in the food industry.
  • Food chemistry.Food Chem.2014 Jun 1;152:291-6. doi: 10.1016/j.foodchem.2013.11.091. Epub 2013 Nov 26.
  • To discover new immunomodulator in the food industry, a water-soluble polysaccharide, CTPB1 was obtained from roots of Cudrania tricuspidata (Carr.) Bur. The average molecular weight of this polysaccharide was estimated to be 4.0×10(4)Da. Monosaccharide composition analysis indicated that the only
  • PMID 24444939
  • Relationships between Serotoninergic System and Skin Fibrotic.
  • Huang J, Gong Q, Huang C, Li G.Author information 48, Xinhua Road, Huadu District, Guangzhou City, Guangdong 510800 China. huangjianguo11@sina.com.AbstractCutaneous fibrosis seen in systemic sclerosis (SSc) is a generalized connective tissue disorder, characterized by a wide spectrum of microvascular and immunological abnormalities. Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter and immune modulator, is also an important mediator of bidirectional interactions between the vasoactive amines and the skin.5-HT, a commonly secreted amine, is a known inducer of fibrosis, although the mechanistic basis for it and growth factors regulating fibrosis and proliferation in the microenvironment are unclear. We review that as serotonin has powerful vasodilator, immunomodulator, and growth factor actions, this pathway could be involved in skin fibrotic. Since serotoninergic system play a role in skin fibrotic, and 5-HTs drugs, an usual treatment for this type of patients. These provides a future perspective for research and drug development.
  • Anti-inflammatory & anti-allergy agents in medicinal chemistry.Antiinflamm Antiallergy Agents Med Chem.2014 Mar;13(1):9-16.
  • Cutaneous fibrosis seen in systemic sclerosis (SSc) is a generalized connective tissue disorder, characterized by a wide spectrum of microvascular and immunological abnormalities. Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter and immune modulator, is also an important mediator of bidir
  • PMID 23909604
  • A systematic review of dual targeting in HER2-positive breast cancer.
  • Kümler I, Tuxen MK, Nielsen DL.Author information Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: Iben.Kumler@regionh.dk.AbstractBACKGROUND: Human epidermal growth factor receptor 2 (HER2) is overexpresed in 15-20% of all breast cancers. Treatment with trastuzumab has led to an improved outcome and prolonged survival of HER2-positive breast cancer patients and today the drug is established as standard of care in both the adjuvant and metastatic settings. However, trastuzumab resistance is common and a major focus in the treatment of HER2-positive breast cancer has been developing therapeutic agents to either potentiate the effect of trastuzumab or to target cells which have become resistant to trastuzumab. The present review addresses efficacy and toxicity of dual targeting in HER2-positive breast cancer.
  • Cancer treatment reviews.Cancer Treat Rev.2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11.
  • BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is overexpresed in 15-20% of all breast cancers. Treatment with trastuzumab has led to an improved outcome and prolonged survival of HER2-positive breast cancer patients and today the drug is established as standard of care in both the adju
  • PMID 24080156

和文文献

  • 多発性骨髄腫のこれまでの治療と最近の治療について
  • 高橋 正知,TAKAHASHI Masatomo
  • 東京女子医科大学雑誌 83(E2), E476-E484, 2013-03-31
  • … ボルテゾミブに続くCalfilzomib、MLN9708(経口薬)、Morizomib、ヒストン脱アセチル化酵素阻害薬であるVorinostatやPanobinostat、第3世代のimmunomodulatorといわれるPomalidomide、モノクロナール抗体のElotuzumabやBT062、さらにBendamustineなどを用いた治療成績も報告され、治療ガイドラインに取り入れられている。 …
  • NAID 110009575055
  • ダニ抗原誘発性難治性皮膚炎に対する新規免疫調節薬FTY720とベタメタゾン軟膏併用療法の有用性 : NC/Ngaマウスを用いた検討
  • 辻 琢己,吉田 侑矢,藤多 哲朗 [他],河野 武幸
  • アレルギー 61(7), 948-958, 2012-07-30
  • 【背景と目的】難治性皮膚炎に対するFTY720とベタメタゾン軟膏併用療法の有用性をNC/Ngaマウスを用いて検討した.【方法】ダニ(Dermatophagoides farinae)抗原で難治性皮膚炎を発症させたNC/Ngaマウスをベタメタゾン吉草酸エステル軟膏(1日1回,週6回塗布), FTY720 (3mg/kg, 2日または3日に1回,週3回経口投与), FTY720+ベタメタゾン併用,軟膏 …
  • NAID 110009489268
  • 自己免疫疾患合併例に対する呼吸器外科手術 (特集 合併症を有する胸部外科手術) -- (呼吸器領域)
  • 門田 嘉久,太田 三徳
  • 胸部外科 65(8), 738-742, 2012-07
  • NAID 40019384305

関連リンク

immunomodulator [im″u-no-mod´u-lāt-er] an agent that causes immunomodulation. biologic response modifier agent that modifies host responses to neoplasms by enhancing immune systems or reconstituting impaired immune ...
:a chemical agent (as methotrexate or azathioprine) that modifies the immune response or the functioning of the immune system (as by the stimulation of antibody ... Seen and Heard What made you want to look up immunomodulator?

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
先読みbiological response modifier
リンク元免疫調節物質」「immunologic factor」「immunological factor」「免疫調節剤
拡張検索immunomodulatory」「immunomodulatory agent

biological response modifier」

  [★] 生物学的応答調節物質 BRM


免疫調節物質」

  [★]

immunomodulator
免疫調節薬生物学的応答調節物質免疫性因子免疫因子免疫調節剤


immunologic factor」

  [★]

biological response modifierimmunological factorimmunomodulator

immunological factor」

  [★]

biological response modifierimmunologic factorimmunomodulator


免疫調節剤」

  [★]

immunomodulatorimmunomodulatory agent
免疫調節物質免疫調節薬

immunomodulatory」

  [★]

  • 免疫調節性の
immunomodulatingimmunoregulatory


immunomodulatory agent」

  [★]

immunomodulator




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡